Tonix Pharmaceuticals Holding Corp. (TNXP)
- Previous Close
0.1570 - Open
0.1503 - Bid 0.1534 x 1000
- Ask 0.1598 x 1000
- Day's Range
0.1500 - 0.1630 - 52 Week Range
0.1200 - 3.3125 - Volume
1,081,950 - Avg. Volume
2,186,082 - Market Cap (intraday)
15.287M - Beta (5Y Monthly) 2.23
- PE Ratio (TTM)
-- - EPS (TTM)
-6.8500 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its development portfolio focuses on central nervous system disorders. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
www.tonixpharma.comRecent News: TNXP
Performance Overview: TNXP
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TNXP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TNXP
Valuation Measures
Market Cap
15.29M
Enterprise Value
152.01k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.14
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.00
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.93%
Return on Equity (ttm)
-74.61%
Revenue (ttm)
7.77M
Net Income Avi to Common (ttm)
-116.66M
Diluted EPS (ttm)
-6.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
24.95M
Total Debt/Equity (mrq)
9.30%
Levered Free Cash Flow (ttm)
-82M